Irinotecan - (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate ;
Irinotecan EP Impurity - C - (S)-4,8,11-triethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate ; (S)-4,8,11-Triethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione-9-yl (1,4'-bipiperidine)-1'-carboxylate; (4S)-4,8,11-triethyl-4-hydroxy-3,14-dioxo-3,4,12,14tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin9-yl 1,4'-bipiperidine-1'-carboxylate;
Irinotecan EP Impurity - E - (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ; (11-ethyl-9-hydroxycamptothecin) ; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3`,4`:6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione;Irinotecan USP Related Compound B ;